Matrix Capital Management Company, LP → Zentalis Pharmaceuticals, Inc. ZNTL

Stake: — Shares: —

Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 27/100 · Filer 90d Win Rate: 50% · Hist. 90d Edge: +8.8%

Filer track record (3 filings): 50% 90d win rate, +8.8% 90d edge
Held by 1 tracked 13F institutional manager
Moderate short days-to-cover (4.8 DTC)

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

0 transactions

0 buys · 0 sales · 0 awards/exercises

Issuer Cluster

2 13D/G filings on this issuer

1 other filing besides this one

Filer Track Record

4 filings by this filer

3 other filings in the data moat

Short Interest · settle 2026-10-15

DTC 4.81

5,986,678 shares short · +0.5% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers

1 holder · $135K

Point72 Asset Mgmt

Other 13D/G Filings on Zentalis Pharmaceuticals, Inc.

Filed	Form	Filer	Stake	Shares
2026-01-02	SCHEDULE	Matrix Capital Management Company, LP	—	—	view →

Other Filings by Matrix Capital Management Company, LP

Filed	Form	Issuer	Stake	Shares
2026-05-11	SCHEDULE 13D/A	Aura Biosciences, Inc. AURA	—	0	view →
2026-01-02	SCHEDULE	Zentalis Pharmaceuticals, Inc. ZNTL	—	—	view →
2025-05-19	SCHEDULE	Aura Biosciences, Inc. AURA	11.17%	6,922,870	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →